Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI9RLZ)

• Drug Name: [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala Drug Info
• Synonyms: [2(R,S)-2-Sulfanylheptanoyl]-phe-ala; [2(R,S)-2-SULFANYLHEPTANOYL]-PHE-ALA; TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5289469
  TTD Drug ID: DMI9RLZ

Molecule-Related Drug Atlas

Drug(s) Targeting Neutral endopeptidase (MME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LCZ696	DMLFX7K	Heart failure	BD10-BD13	Approved	[3]
Candoxatril	DMHJCGV	Hypertension	BA00-BA04	Phase 3	[4]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[5]
SLV 306	DMCDON3	Acute decompensated heart failure	BD1Z	Phase 2	[6]
SLV-334	DMXCJKY	Brain injury	NA07.Z	Phase 2	[7]
VX-15	DMLWM4G	Huntington disease	8A01.10	Phase 2	[8]
Sampatrilat	DMXTOVE	Hypotension	BA20-BA21	Phase 2	[9]
SLV-338	DM7WKTM	Cardiovascular disease	BA00-BE2Z	Phase 1	[10]
GW-796406	DMQ46DN	Hypotension	BA20-BA21	Phase 1	[5]
Debio 0827	DMQIEFB	Chronic pain	MG30	Phase 1	[11]

Drug(s) Targeting Poly [ADP-ribose] polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide	DMUPE07	Acne vulgaris	ED80	Approved	[12]
KU-0058948	DMSA4HZ	Ovarian cancer	2C73	Approved	[13]
Niraparib Tosylate	DMLPSWQ	Fallopian tube cancer	2C74	Approved	[14]
CC-486	DMTNQB0	Acute myeloid leukaemia	2A60	Phase 3	[15]
Nicaraven	DMFBNA3	Cerebrovascular disease	8B2Z	Phase 3	[16]
PMID27841036-Compound-37	DM0OVZ2	Ovarian cancer	2C73	Phase 2	[17]
Stenoparib	DMKVBL8	Ovarian cancer	2C73	Phase 2	[18]
AG140699	DMA9FKY	Melanoma	2C30	Phase 2	[19]
AZD5305	DMW9R1C	Prostate cancer	2C82.0	Phase 2	[20]
AMXI 5001	DMR9H6B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neutral endopeptidase (MME)	TT5TKPM	NEP_HUMAN	Inhibitor	[2]
Poly [ADP-ribose] polymerase 1 (PARP1)	TTVDSZ0	PARP1_HUMAN	Inhibitor	[1]

References

• [1] Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
• [5] Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
• [6] The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
• [7] Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
• [10] Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
• [11] Clinical pipeline report, company report or official report of Debiopharm (2011).
• [12] beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
• [13] Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
• [16] Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
• [17] PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
• [18] Clinical pipeline report, company report or official report of Allarity Therapeutics.
• [19] Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
• [20] Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736.
• [21] AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.